Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

The completion of this study may positively influence Pfizer’s stock performance by demonstrating the effectiveness and safety of INLYTA® in real-world settings, potentially boosting investor ...

Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

Listen and subscribe to Stocks In Translation on Apple Podcasts, Spotify, or wherever you find your favorite podcast.Nvidia’s (NVDA) explosive growth is doing more than lifting portfolios - it’s ...

The purpose of investing in stocks is to make money, not lose it. So selling shares at a loss can be very upsetting. In this ...

This was the stock's third consecutive day of losses.

This was the stock's second consecutive day of losses.

Pfizer (NYSE: PFE) was on top of the world when it came to earnings and stock price performance. This was in early pandemic ...

Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.